Comparative Pharmacology
Head-to-head clinical analysis: ISOVUE 200 versus ISOVUE 300.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISOVUE 200 versus ISOVUE 300.
ISOVUE-200 vs ISOVUE-300
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated contrast medium that attenuates X-rays, providing radiographic contrast by increasing the density of blood vessels and tissues.
Iodinated radiocontrast agent that attenuates X-rays, providing enhanced visualization of vascular structures and body cavities during imaging procedures.
Intravenous administration of 1.0-2.0 mL/kg (200 mg iodine/mL) for computed tomography; intra-arterial doses vary by procedure, typically 5-80 mL total. Maximum recommended dose: 2.0 mL/kg.
Intravenous: 50-150 mL (up to 300 mg iodine/kg) as a bolus or infusion; intra-arterial: 5-40 mL depending on procedure; intrathecal: 8-15 mL. Maximum total iodine dose: 300 mg iodine/kg.
None Documented
None Documented
2 hours in normal renal function; prolongs up to 30 hours in severe renal impairment. Closely correlates with creatinine clearance.
Terminal elimination half-life in patients with normal renal function is approximately 2 hours. In patients with moderate to severe renal impairment (creatinine clearance <30 mL/min), the half-life can be prolonged up to 20–40 hours, requiring dose adjustment.
Renal: 100% unchanged as iohexol; glomerular filtration with no tubular reabsorption. No biliary/fecal elimination.
Primarily renal (glomerular filtration), with >95% of administered dose excreted unchanged in urine within 24 hours. Less than 1% is excreted via bile/fecal route.
Category C
Category C
Contrast Media
Contrast Media